Finance

Beta
Ask
Lists
CVS:NYSE
CVS Health Corp
$101.57
0.00%
(0.00) 1D
$101.69
+0.12% (+0.12)
Pre-market
Closed: Jun 23, 4:00:05 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CVS...
Mkt. cap
129.60B
Avg. vol.
8.85M
Volume
1.09K
Dividend
2.62%
Quarterly dividend
$0.67
Ex-dividend date
Apr 23, 2026
P/E ratio
44.92
52-wk high
$103.12
52-wk low
$58.50
EPS
$2.26
Beta
0.63
Shares outstanding
1.28B
No. of employees
260K
Mkt. cap
129.60B
Avg. vol.
8.85M
Volume
1.09K
Dividend
2.62%
Quarterly dividend
$0.67
Ex-dividend date
Apr 23, 2026
P/E ratio
44.92
52-wk high
$103.12
52-wk low
$58.50
EPS
$2.26
Beta
0.63
Shares outstanding
1.28B
No. of employees
260K
News stories
From sources across the web
Profile
CVS Health Corporation is an American multinational healthcare company that owns CVS Pharmacy, a retail pharmacy chain; CVS Caremark, a pharmacy benefits manager; and Aetna, a health insurance provider, among many other brands. The company is the world's second largest healthcare company, behind UnitedHealth Group. In 2023, the company was ranked 64th in the Forbes Global 2000. CVS started in Lowell, Massachusetts by brothers Stanley and Sidney Goldstein and their partner Ralph Hoagland. The name stood for Consumer Value Stores. Wikipedia
About CVS Health Corp
CEODavid Joyner
Employees260K
Founded1963
HeadquartersWoonsocket, Rhode Island, United States
SectorHealth care provider
Websitecvshealth.com
Analyst Ratings
Based on 17 analysts giving stock ratings to CVS in the past 3 months
Strong Buy
Buy
17
Hold
0
Sell
0
12 month forecast
Based on 17 Wall Street analysts offering 12 month price targets for CVS in the last 3 months.
Highest
Current $101.57
$115.00 (+13.22%)
Average
$105.56 (+3.93%)
Lowest
$92.00 (-9.42%)
Analyst
Recommendation
Action
Price Target
Projected
Date
Allen Lutz
Bank of America Securities
Buy
Reiterated
$110.00
+8.3%
06/22/2026
Lance Wilkes
Bernstein
Buy
Maintained
$106.00
+4.4%
06/09/2026
Kevin Caliendo
UBS
Buy
Maintained
$115.00
+13.2%
06/08/2026
Ann Hynes
Mizuho Securities
Buy
Maintained
$115.00
+13.2%
06/08/2026
Stephen Baxter
Wells Fargo
Buy
Maintained
$103.00
+1.4%
06/04/2026
Erin Wright
Morgan Stanley
Buy
Maintained
$111.00
+9.3%
06/04/2026
David S Macdonald
Truist Financial
Buy
Maintained
$108.00
+6.3%
06/01/2026
Lisa Gill
J.P. Morgan
Buy
Maintained
-
-
05/27/2026
Andrew Mok CFA
Barclays
Buy
Maintained
$106.00
+4.4%
05/26/2026
Steven Silver
Argus Research
Buy
Maintained
$104.00
+2.4%
05/13/2026
Charles Rhyee
TD Cowen
Buy
Reiterated
$110.00
+8.3%
05/11/2026
George Hill
Deutsche Bank
Buy
Maintained
$92.00
-9.4%
05/07/2026
Elizabeth Anderson CFA
Evercore ISI
Buy
Maintained
$105.00
+3.4%
05/07/2026
Ben Hendrix
RBC Capital
Buy
Reiterated
$107.00
+5.3%
05/06/2026
Scott Fidel
Goldman Sachs
Buy
Maintained
$104.00
+2.4%
05/07/2026
Michael Ha
Robert W. Baird
Buy
Maintained
$94.00
-7.5%
04/15/2026
Courtney Breen
Bernstein
Buy
Maintained
$94.00
-7.5%
03/30/2026
Jessica Tassan
Piper Sandler
Buy
Reiterated
$99.00
-2.5%
03/31/2026
Michael Cherny
Leerink Partners
Buy
Reiterated
$98.00
-3.5%
03/24/2026
Sarah James
Cantor Fitzgerald
Buy
Maintained
$95.00
-6.5%
02/10/2026
Unknown Analyst
Oppenheimer
Hold
Reiterated
-
-
02/11/2026
Last report
May 6, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
$2.57 / $2.21
+16.48%beat
Revenue / Est. (USD)
99.85B / 95.02B
+5.09%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
98.43B
102.24B
105.10B
99.85B
Cost of goods sold
85.32B
89.06B
92.13B
84.80B
Cost of revenue
85.32B
89.06B
92.13B
84.80B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
10.35B
10.86B
11.32B
10.93B
Operating expense
10.35B
10.86B
11.32B
10.93B
Total operating expenses
95.67B
99.92B
103.45B
95.73B
Operating income
2.76B
2.32B
1.65B
4.12B
Other non operating income
29.00M
26.00M
-88.00M
32.00M
EBT including unusual items
1.65B
-3.48B
1.35B
3.94B
EBT excluding unusual items
2.51B
2.19B
1.37B
3.95B
Income tax expense
634.00M
508.00M
-1.57B
981.00M
Effective tax rate
38.49%
-14.59%
-115.88%
24.91%
Other operating expenses
-
-
-
-
Net income
1.02B
-3.98B
2.94B
2.94B
Net profit margin
1.04%
-3.89%
2.80%
2.95%
Earnings per share
1.81
1.60
1.09
2.57
Interest and investment income
487.00M
632.00M
594.00M
574.00M
Interest expense
-763.00M
-784.00M
-787.00M
-774.00M
Net interest expenses
-276.00M
-152.00M
-193.00M
-200.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
3.93B
3.45B
2.80B
5.23B
Gain or loss from assets sale
-
-483.00M
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer